Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China.

Liu, Haonan; Qin, Xiaobing; Xu, Zhiyuan; Wu, Meng; Lu, Tong; Zhou, Shuang; Yao, Nan; Liu, Suya; Shao, Yong; Han, Zhengxiang

Liu, Haonan; Qin, Xiaobing; Xu, Zhiyuan; Wu, Meng; Lu, Tong; Zhou, Shuang; Yao, Nan; Liu, Suya; Shao, Yong; Han, Zhengxiang.

Affiliation

Liu H; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Qin X; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Xu Z; Department of Emergency, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Wu M; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Lu T; Department of Gastroenterology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Zhou S; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Yao N; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Liu S; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Shao Y; Department of General Surgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Han Z; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.

Front Genet ; 13: 1000448, 2022.

Article in En | MEDLINE | ID: mdl-36160021

Key words

camrelizumab; effectiveness; hepatitis B virus; hepatocellular carcinoma; immunotherapy; safety

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Front Genet Year: 2022 Document type: Article Affiliation country: China

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google